Attenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells.
dc.contributor.author | Sakthivel, Priya | |
dc.contributor.author | Gereke, Marcus | |
dc.contributor.author | Breithaupt, Angele | |
dc.contributor.author | Fuchs, Dietmar | |
dc.contributor.author | Gigliotti, Luca | |
dc.contributor.author | Gruber, Achim D | |
dc.contributor.author | Dianzani, Umberto | |
dc.contributor.author | Bruder, Dunja | |
dc.date.accessioned | 2014-07-18T09:38:37Z | |
dc.date.available | 2014-07-18T09:38:37Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Attenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells. 2014, 9 (7):e100970 PLoS ONE | en |
dc.identifier.issn | 1932-6203 | |
dc.identifier.pmid | 25029240 | |
dc.identifier.doi | 10.1371/journal.pone.0100970 | |
dc.identifier.uri | http://hdl.handle.net/10033/323399 | |
dc.description.abstract | Inducible Co-stimulator (ICOS) plays a critical role in mediating T cell differentiation and function and is considered a key player in balancing T effector and T regulatory (Treg) cell responses. Here we show that activation of the ICOS signalling pathway during acute influenza A virus (IAV) infection by application of an agonistic ICOS antibody reduced the frequency of CD8+ T cells in the respiratory tract of IAV infected animals and delayed pathogen elimination. In line with this, immune-mediated influenza pneumonia was significantly ameliorated in mice that received ICOS agonist as indicated by significantly reduced alveolar infiltrations and bronchointerstitial pneumonia, while at the same time virus-related pathology remained unaffected. Importantly, ICOS agonist treatment resulted in expansion of CD4+Foxp3+ Tregs in IAV infected mice, which was associated with elevated levels of the immunosuppressive cytokine IL-10 in the alveolar space. Together, our findings suggest a prominent role of ICOS signaling during acute IAV infection by increasing the Treg/CD8+ T cell ratio with beneficial outcome on immune-mediated pneumonia and underline the suitability of ICOS as potential therapeutic target for immune intervention in those infectious conditions characterized by strong immunopathology rather than virus-mediated cytopathic effects. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to PloS one | en |
dc.title | Attenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells. | en |
dc.type | Article | en |
dc.identifier.journal | PloS one | en |
refterms.dateFOA | 2018-06-12T22:57:13Z | |
html.description.abstract | Inducible Co-stimulator (ICOS) plays a critical role in mediating T cell differentiation and function and is considered a key player in balancing T effector and T regulatory (Treg) cell responses. Here we show that activation of the ICOS signalling pathway during acute influenza A virus (IAV) infection by application of an agonistic ICOS antibody reduced the frequency of CD8+ T cells in the respiratory tract of IAV infected animals and delayed pathogen elimination. In line with this, immune-mediated influenza pneumonia was significantly ameliorated in mice that received ICOS agonist as indicated by significantly reduced alveolar infiltrations and bronchointerstitial pneumonia, while at the same time virus-related pathology remained unaffected. Importantly, ICOS agonist treatment resulted in expansion of CD4+Foxp3+ Tregs in IAV infected mice, which was associated with elevated levels of the immunosuppressive cytokine IL-10 in the alveolar space. Together, our findings suggest a prominent role of ICOS signaling during acute IAV infection by increasing the Treg/CD8+ T cell ratio with beneficial outcome on immune-mediated pneumonia and underline the suitability of ICOS as potential therapeutic target for immune intervention in those infectious conditions characterized by strong immunopathology rather than virus-mediated cytopathic effects. |